222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1800020241	2019-01-01	2018-12-20	Investigation for Risk Factors of Membrane Nephropathy in Guangxi and Study for Intervention of Vita ...	Disease diagnosis and treatment technology and standardized research and development and application ...	Idiopathic membranous nephropathy	Vitamin Dgroup:Active Vitamin D0.5ug/day;Valsartangroup:Valsartancapsule 160mg/day;Combined treatmen ...	The People's Hospital of Guangxi Zhuang Autonomous Region	NULL	Recruiting	14	100	Both	Vitamin D group:40;Valsartan group:40;Combined treatment group:40;		China
2	NCT01129557 (ClinicalTrials.gov)	September 2009	21/5/2010	Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinur ...	Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan ...	Proteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal S ...	Drug: Aliskiren;Drug: Valsartan	Columbia University	Novartis Pharmaceuticals	Terminated	18 Years	N/A	All	46	Phase 4	United States
3	NCT00518219 (ClinicalTrials.gov)	July 2007	16/8/2007	To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartanin the Membranous ...	To Compare the Efficacy and Safety of TW vs Valsartan in the MN	Membranous Nephropathy	Drug: TW	Nanjing University School of Medicine	NULL	Completed	18 Years	65 Years	Both	68	Phase 4	China

First Previous1Next Last